Pfizer receives early clearance from FTC for Metsera acquisition

Pfizer (PFE) announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Metsera (MTSR). The termination of the waiting period under the HSR Act satisfies the regulatory review requirements under the previously announced proposed acquisition of Metsera, which was set to expire on November 7. The Fly notes that Novo Nordisk (NVO) is also attempting to acquire Metsera.